This review provides practical guidance on the clinical management of target-specific oral anticoagulants, addressing periprocedural care, effect measurement, and the lack of antidotes.
Answers are grounded in this paper and cite their sources.
May inform periprocedural management of target-specific oral anticoagulants; leaves open validation of monitoring and antidotes in prospective studies.
More than 4 years have passed since the first approval of a target-specific oral anticoagulant (TSOAC) in the United States, and the number of clinicians who have prescribed (or considered prescribing) one or more of these medications is increasing. Although these agents may, in properly selected patients, offer advantages over more traditional therapies, their lack of familiarity can be intimidating. Clinicians who are prescribing the TSOACs face a number of management questions not definitively answered by the registration trials. This chapter reviews some of these situations, including updated information on the periprocedural management of TSOACs and the latest evidence about how to best measure TSOAC effect. The lack of an antidote and other considerations that may be relevant when deciding between newer and more traditional anticoagulant medications are also discussed.
No takes yet. Share an insight, caveat, or question.
David García (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: